Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0V4UO
|
||||
| Former ID |
DIB005267
|
||||
| Drug Name |
M-16209
|
||||
| Synonyms |
1-(3-Bromo-benzo[b]furan-2-ylsulfonyl)imidazolidine-2,4-dione; 1-(3-Bromobenzo[b]furan-2-ylsulfonyl)hydantoin
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Diabetes [ICD9: 253.5, 588.1; ICD10:E23.2, N25.1] | Phase 2 | [1] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C11H7BrN2O5S
|
||||
| Canonical SMILES |
C1C(=O)NC(=O)N1S(=O)(=O)C2=C(C3=CC=CC=C3O2)Br
|
||||
| InChI |
1S/C11H7BrN2O5S/c12-9-6-3-1-2-4-7(6)19-10(9)20(17,18)14-5-8(15)13-11(14)16/h1-4H,5H2,(H,13,15,16)
|
||||
| InChIKey |
ZJSUDHQFSBHLDV-UHFFFAOYSA-N
|
||||
| CAS Number |
CAS 128851-36-5
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| Target and Pathway | |||||
| Target(s) | Aldose reductase | Target Info | Inhibitor | [2], [3] | |
| BioCyc Pathway | Methylglyoxal degradation III | ||||
| Acetone degradation I (to methylglyoxal) | |||||
| KEGG Pathway | Pentose and glucuronate interconversions | ||||
| Fructose and mannose metabolism | |||||
| Galactose metabolism | |||||
| Glycerolipid metabolism | |||||
| Metabolic pathways | |||||
| NetPath Pathway | IL1 Signaling Pathway | ||||
| TGF_beta_Receptor Signaling Pathway | |||||
| PathWhiz Pathway | Fructose and Mannose Degradation | ||||
| Pyruvate Metabolism | |||||
| Pterine Biosynthesis | |||||
| Glycerolipid Metabolism | |||||
| Galactose Metabolism | |||||
| WikiPathways | Metapathway biotransformation | ||||
| Polyol Pathway | |||||
| Metabolism of steroid hormones and vitamin D | |||||
| References | |||||
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000031) | ||||
| REF 2 | Effects of novel aldose reductase inhibitors, M16209 and M16287, on streptozotocin-induced diabetic neuropathy in rats. Eur J Pharmacol. 1991 Feb 7;193(2):185-91. | ||||
| REF 3 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.